Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] stock went on an upward path that rose over 2.32% on Thursday, amounting to a one-week price decrease of less than -34.47%. The company report on January 4, 2021 that Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences.
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced that Armando Anido, Chief Executive Officer of Zynerba, will participate in two upcoming virtual investor conferences. Mr. Anido will participate in a fireside chat during the H.C. Wainwright BioConnect Conference which will be available on demand January 11-14, 2021. He will also present a company overview during the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m. ET.
Investors interested in arranging a virtual meeting with the Company’s management during the ICR Conference 2021 should contact the conference coordinator or firstname.lastname@example.org. Webcasts of both conferences will be accessible under the Events & Webcasts tab of the Investor section of Zynerba’s website at www.zynerba.com.
Over the last 12 months, ZYNE stock rose by 19.33%. The one-year Zynerba Pharmaceuticals Inc. stock forecast points to a potential upside of 22.64. The average equity rating for ZYNE stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $183.28 million, with 29.24 million shares outstanding and 28.60 million shares in the current float. Compared to the average trading volume of 4.78M shares, ZYNE stock reached a trading volume of 10587630 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Zynerba Pharmaceuticals Inc. [ZYNE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZYNE shares is $7.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZYNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Zynerba Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 21, 2020. The new note on the price target was released on July 01, 2020, representing the official price target for Zynerba Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $12, while ROTH Capital analysts kept a Buy rating on ZYNE stock.
The Average True Range (ATR) for Zynerba Pharmaceuticals Inc. is set at 0.81 The Price to Book ratio for the last quarter was 2.52, with the Price to Cash per share for the same quarter was set at 2.01.
ZYNE Stock Performance Analysis:
Zynerba Pharmaceuticals Inc. [ZYNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -34.47. With this latest performance, ZYNE shares gained by 56.83% in over the last four-week period, additionally plugging by 48.32% over the last 6 months – not to mention a rise of 19.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZYNE stock in for the last two-week period is set at 57.55, with the RSI for the last a single of trading hit 55.67, and the three-weeks RSI is set at 58.22 for Zynerba Pharmaceuticals Inc. [ZYNE]. The present Moving Average for the last 50 days of trading for this stock 4.10, while it was recorded at 5.78 for the last single week of trading, and 4.13 for the last 200 days.
Insight into Zynerba Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for ZYNE is now -51.40, given the latest momentum, and Return on Invested Capital for the company is -49.42. Return on Equity for this stock declined to -49.47, with Return on Assets sitting at -42.48. When it comes to the capital structure of this company, Zynerba Pharmaceuticals Inc. [ZYNE] has a Total Debt to Total Equity ratio set at 0.47. Additionally, ZYNE Total Debt to Total Capital is recorded at 0.47, with Total Debt to Total Assets ending up at 0.40. Long-Term Debt to Equity for the company is recorded at 0.15, with the Long-Term Debt to Total Capital now at 0.14.
Reflecting on the efficiency of the workforce at the company, Zynerba Pharmaceuticals Inc. [ZYNE] managed to generate an average of -$1,176,557 per employee.Zynerba Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.10.
ZYNE Stock EPS
With the latest financial reports released by the company, Zynerba Pharmaceuticals Inc. posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 8.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZYNE.
Zynerba Pharmaceuticals Inc. [ZYNE] Insider Position Details
There are presently around $37 million, or 24.10% of ZYNE stock, in the hands of institutional investors. The top three institutional holders of ZYNE stocks are: ETF MANAGERS GROUP, LLC with ownership of 1,814,328, which is approximately 103.623% of the company’s market cap and around 3.10% of the total institutional ownership; VANGUARD GROUP INC, holding 1,035,402 shares of the stock with an approximate value of $5.94 million in ZYNE stocks shares; and MIRAE ASSET GLOBAL INVESTMENTS CO., LTD., currently with $3.73 million in ZYNE stock with ownership of nearly 59.575% of the company’s market capitalization.
Positions in Zynerba Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 28 institutional holders increased their position in Zynerba Pharmaceuticals Inc. [NASDAQ:ZYNE] by around 2,125,967 shares. Additionally, 30 investors decreased positions by around 1,120,228 shares, while 18 investors held positions by with 3,219,093 shares. The mentioned changes placed institutional holdings at 6,465,288 shares, according to the latest SEC report filing. ZYNE stock had 8 new institutional investments in for a total of 201,534 shares, while 17 institutional investors sold positions of 842,605 shares during the same period.